TY - JOUR T1 - Recent advances in genetically modified animal models of glaucoma and their roles in drug repositioning JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 161 LP - 166 DO - 10.1136/bjophthalmol-2018-312724 VL - 103 IS - 2 AU - Chikako Harada AU - Atsuko Kimura AU - Xiaoli Guo AU - Kazuhiko Namekata AU - Takayuki Harada Y1 - 2019/02/01 UR - http://bjo.bmj.com/content/103/2/161.abstract N2 - Glaucoma is one of the leading causes of vision loss in the world. Currently, pharmacological intervention for glaucoma therapy is limited to eye drops that reduce intraocular pressure (IOP). Recent studies have shown that various factors as well as IOP are involved in the pathogenesis of glaucoma, especially in the subtype of normal tension glaucoma. To date, various animal models of glaucoma have been established, including glutamate/aspartate transporter knockout (KO) mice, excitatory amino acid carrier 1 KO mice, optineurin E50K knock-in mice, DBA/2J mice and experimentally induced models. These animal models are very useful for elucidating the pathogenesis of glaucoma and for identifying potential therapeutic targets. However, each model represents only some aspects of glaucoma, never the whole disease. This review will summarise the benefits and limitations of using disease models of glaucoma and recent basic research in retinal protection using existing drugs. ER -